Stock AVIR ATEA PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-06-28 EDT 		5-day change 1st Jan Change
3.31 USD -2.07% Intraday chart for Atea Pharmaceuticals, Inc. -3.78% +8.52%
06-05 Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024 CI
05-22 Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Atea Pharmaceuticals : Jefferies Global Healthcare Conference Presentation
PU
Atea Pharmaceuticals : Absorption, Distribution, Metabolism, and Excretion of Bemnifosbuvir in Rats (SAT 411)
PU
Atea Pharmaceuticals : Lead in Cohort Results From a Phase 2 Study of a Novel 8 Week Combination Regimen of Bemnifosbuvir and Ruzasvir in Patients with Chronic Hepatitis C Virus Infection (THU 382)
PU
Atea Pharmaceuticals : Low Risk of Drug Drug Interactions for Ruzasvir Based Upon In Vitro Metabolism and Transporter Interaction Studies (SAT 412)
PU
Atea Pharmaceuticals Presents Positive Initial Phase 2 Data for Bemnifosbuvir and Ruzasvir Combination for Treatment of Hepatitis C Virus at EASL Congress 2024
AQ
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
AQ
Atea Pharmaceuticals Presents New Data Showcasing Potential Best-in-Class Combination Profile of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2024
AQ
Atea Pharmaceuticals : First Quarter 2024 Financial Results Conference Call Presentation
PU
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
AQ
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
AQ
Atea Announces Presentation of Data Highlighting Favorable Safety Profile of Bemnifosbuvir at ESCMID Global 2024
AQ
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
AQ
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
AQ
Atea Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
AQ
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
AQ
Atea Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
AQ
Atea Pharmaceuticals Presents Promising Bemnifosbuvir and Ruzasvir Combination Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
AQ
Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
AQ
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
AQ
Atea Pharmaceuticals to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD The Liver Meeting 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AVIR Stock
  4. News Atea Pharmaceuticals, Inc.
  5. Press Releases